



Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/552,015	
			Filing Date	October 11, 2005	
			First Named Inventor	Nobuhiro Umeda	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	20241/0203472-USO

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code*+Number*+Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
NO	BA	WO-01/14834A1	03-01-2001	TAKEDA CHEMICAL INDUSTRIES, LTD.		
↓	BB	CA-2382418A1	03-01-2001	TAKEDA CHEMICAL INDUSTRIES, LTD.		
	BC	WO-01/058610A1	09-20-2001	TAISHO PHARMACEUTICAL CO., LTD		
	BD	WO-03/022821A1	03-20-2003	TAISHO PHARMACEUTICAL CO., LTD.		
	BE	JP-8-503922	04-30-1996			
	BF	WO-93/20057	10-14-1993	MERRELL DOW PHARMACEUTICALS INC.		
	BG	JP-5-140142	06-08-1993			
	BH	EP-0483772A1	05-06-1992	TAKEDA CHEMICAL INDUSTRIES, LTD.		
	BI	JP-5-310724	11-22-1993			
	BJ	JP-2-288856	11-28-1990			
	BK	EP-0377450A1	07-11-1990	E.I. DU PONT DE NEMOURS AND COMPANY		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			Y ²
NO	CA	SCOTT JOHN W., et al., "6-Hydroxychroman-2-carboxylic Acids: Novel Antioxidants 1" Journal of the American Oil Chemists' Society, Vol. 51, pp. 200-203.			
	CB	CYRUS TILLMAN, et al., "Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice". The Journal of Clinical Investigation. June 1999, Vol. 103, Number 11, pp.1597-1604.			
	CC	ANDERSON RE, et al. "Free radicals and ocular disease", Adv. Exp. Med. Biol. 1994; 368: pp.73-86.			
	CD	NISHIGORI H, et al., "The alteration of lipid peroxide in glucocorticoid-induced cataract of developing chick embryos and the effect of the ascorbic acid.", Curr Eye Res. 1986 Jan;5(1): 37-40.			
	CE	HIRAMITSU T, et al. "Preventive effect of antioxidants on lipid peroxidation in the retina."			
Examiner Signature	/Taylor Oh/ (05/28/2008)			Date Considered	05/28/2008



Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/552,015
Filing Date	October 11, 2005
First Named Inventor	Nobuhiro Umeda
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	20241/0203472-USO

NOI	Ophthalmic Res. 1991;23(4):196-203.	
CF	Vitamin Information Center (Tokyo), VIC Newsletter, 105, 4, 2002.	
CG	J. Act. Free Rad., Vol.3, No. 4, 1992, pp.444-449	
CH	SOLBACH U, et al., "Imaging of retinal autofluorescence in patients with age-related macular degeneration.", Retina., 1997; 17(5): 385-389.	
CI	Patent Abstracts of Japan for 2004-010513 published January 15, 2004.	
CJ	HARDER DR., "Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone.", J Vasc Res. 1995 Mar-Apr; 32(2):79-92.	
CK	MCGIFF JOHN C., et al., "20-HETE and the kidney: resolution of old problems and new beginnings.", Invited Review, the American Physiological Society, 1999, pp.R607-R623.	
CL	ROMAN RICHARD J., "P-450 Metabolites of Arachidonic Acid in the Control of Cardiovascular Function, Physiol Rev, Vol. 82, January 2002, pp.131-186.	
CM	C. D. FUNK, "Lipids and Lipid Metabolism", Biochimica et Biophysica Acta 1304, 1996, pp.65-84.	
CN	ANDERSON ROBERT E. et al., "Free Radicals and Ocular Disease", pp. 73-86	
CO	NISHIGORI HIDEO, et al., "The Alteration of Lipid Peroxide in Glucocorticoid-induced Cataract of Developing Chick Embryos and the Effect of Absorbic Acid.", Current Eye Res., Vol. 5, No. 1, 1986, pp.37-40.	
CP	TRUSCOTT R.J.W., et al., "The state of sulphhydryl groups in normal and cataractous human lenses.", Exp. Eye Res., 1997, Vol. 25, 139-148.	
CQ	HIRAMITSU TADAHISA, et al., "Preventive effect of antioxidants on lipid peroxidation in the retina.", Ophthalmic Res, 1991; Vol. 23; pp.196-203.	
CR	SOLBACH UTA MD, et al., "Imaging of retinal autofluorescence in patients with age-related macular degeneration.", Retina, Journal of Retinal and Vitreous diseases, 1997, Vol. 17, No. 5, pp. 385-389.	
CS	OHKAWA S., et al., "5-Aminocoumarins: Dual Inhibitors of Lipid Peroxidation and Dopamine Release with Protective Effects Against Central Nervous System Trauma and Ischemia.", Journal of Med. Chem. 1997, Vol. 40, pp.559-573.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Taylor Oh/ (05/28/2008)	Date Considered	05/28/2008
--------------------	--------------------------	-----------------	------------